Interestingly, we found that the TLR9 agonist CpG ODN downregulated the expression of Wnt2b in HCC-TAMs and inhibited the activation of β-catenin, thus reversing the M2 polarization. This evidence concerns the gene WNT2B and hepatocellular carcinoma.